As the pipelines of their pharmaceutical and biotech clients continue to yield new drugs for patients, agencies are also seeing their business grow.
Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.
According to closerlook’s leaders, agency growth in 2013 reflects the value of its commitment to smarter marketing. Investments in the agency’s services by new and existing clients led to increases of 44 percent in revenue and 56 percent in staff – including the creation of several c-suite positions.
The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies.
From big pharma to smaller specialty entities, contract manufacturing serves as a strategy for various industry players.
The global market for consumer-care products generated slower growth in 2010 than during the previous year, partially because of a weaker flu season in North America and Europe.
Big Pharma started the new decade where it left off in 2009 by continuing to conduct a flurry of deals amongst each other and with many other types of companies throughout the healthcare industry.